$NVAX @ 1.10
https://investorshangout.com/post/view?id=4593229
Novavax logoNovavax, Inc. (NASDAQ:NVAX) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 60,224,878 shares, a growth of 3.4% from the April 28th total of 58,260,240 shares. Based on an average daily volume of 9,235,079 shares, the short-interest ratio is currently 6.5 days. Approximately 22.5% of the shares of the company are sold short.
In other news, insider Stanley C. Erck bought 50,000 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average cost of $0.84 per share, with a total value of $42,000.00. Following the completion of the transaction, the insider now owns 128,279 shares of the company’s stock, valued at approximately $107,754.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders acquired 105,000 shares of company stock worth $90,800 over the last three months. Insiders own 3.50% of the company’s stock.
Get Novavax Inc. alerts:
A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Novavax by 4.5% in the first quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after buying an additional 938,581 shares during the last quarter. State Street Corp boosted its position in Novavax by 99.2% in the fourth quarter. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company’s stock worth $25,163,000 after buying an additional 9,947,481 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Novavax by 41.9% in the first quarter. JPMorgan Chase & Co. now owns 3,708,105 shares of the biopharmaceutical company’s stock worth $4,746,000 after buying an additional 1,095,388 shares during the last quarter. Norges Bank acquired a new position in Novavax during the fourth quarter worth $3,300,000. Finally, Geode Capital Management LLC boosted its position in Novavax by 18.3% in the first quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock worth $3,073,000 after buying an additional 371,295 shares during the last quarter. 51.15% of the stock is owned by institutional investors.
Several brokerages have issued reports on NVAX. Zacks Investment Research cut Novavax from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Chardan Capital reaffirmed a “hold” rating and issued a $1.50 price objective on shares of Novavax in a research note on Tuesday, February 28th. Ladenburg Thalmann Financial Services reaffirmed a “neutral” rating on shares of Novavax in a research note on Wednesday, March 1st. Cantor Fitzgerald set a $2.00 price objective on Novavax and gave the stock a “hold” rating in a research note on Monday, May 8th. Finally, ValuEngine downgraded Novavax from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $5.56.
Shares of Novavax (NVAX) traded up 5.77% during mid-day trading on Friday, reaching $1.10. The company had a trading volume of 18,419,883 shares. The stock has a 50 day moving average of $0.97 and a 200-day moving average of $1.20. Novavax has a 52 week low of $0.73 and a 52 week high of $8.49. The company’s market capitalization is $310.85 million.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $6.17 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,466.36%. Novavax’s quarterly revenue was up 34.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) EPS. On average, analysts expect that Novavax will post ($0.61) earnings per share for the current fiscal year.
About Novavax
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
https://investorshangout.com/post/view?id=4593229
Novavax logoNovavax, Inc. (NASDAQ:NVAX) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 60,224,878 shares, a growth of 3.4% from the April 28th total of 58,260,240 shares. Based on an average daily volume of 9,235,079 shares, the short-interest ratio is currently 6.5 days. Approximately 22.5% of the shares of the company are sold short.
In other news, insider Stanley C. Erck bought 50,000 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average cost of $0.84 per share, with a total value of $42,000.00. Following the completion of the transaction, the insider now owns 128,279 shares of the company’s stock, valued at approximately $107,754.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders acquired 105,000 shares of company stock worth $90,800 over the last three months. Insiders own 3.50% of the company’s stock.
Get Novavax Inc. alerts:
A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Novavax by 4.5% in the first quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after buying an additional 938,581 shares during the last quarter. State Street Corp boosted its position in Novavax by 99.2% in the fourth quarter. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company’s stock worth $25,163,000 after buying an additional 9,947,481 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Novavax by 41.9% in the first quarter. JPMorgan Chase & Co. now owns 3,708,105 shares of the biopharmaceutical company’s stock worth $4,746,000 after buying an additional 1,095,388 shares during the last quarter. Norges Bank acquired a new position in Novavax during the fourth quarter worth $3,300,000. Finally, Geode Capital Management LLC boosted its position in Novavax by 18.3% in the first quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock worth $3,073,000 after buying an additional 371,295 shares during the last quarter. 51.15% of the stock is owned by institutional investors.
Several brokerages have issued reports on NVAX. Zacks Investment Research cut Novavax from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Chardan Capital reaffirmed a “hold” rating and issued a $1.50 price objective on shares of Novavax in a research note on Tuesday, February 28th. Ladenburg Thalmann Financial Services reaffirmed a “neutral” rating on shares of Novavax in a research note on Wednesday, March 1st. Cantor Fitzgerald set a $2.00 price objective on Novavax and gave the stock a “hold” rating in a research note on Monday, May 8th. Finally, ValuEngine downgraded Novavax from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $5.56.
Shares of Novavax (NVAX) traded up 5.77% during mid-day trading on Friday, reaching $1.10. The company had a trading volume of 18,419,883 shares. The stock has a 50 day moving average of $0.97 and a 200-day moving average of $1.20. Novavax has a 52 week low of $0.73 and a 52 week high of $8.49. The company’s market capitalization is $310.85 million.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $6.17 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,466.36%. Novavax’s quarterly revenue was up 34.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) EPS. On average, analysts expect that Novavax will post ($0.61) earnings per share for the current fiscal year.
About Novavax
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
2
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
